Previously, the FDA required that RWE submissions include private, confidential information at the individual patient level. This requirement made it impractical to use many large databases containing ...

The FDA approved fam-trastuzumab derextecan-nki (Enhertu; Daiichi Sankyo, Inc), a HER2-directed antibody-drug conjugate (ADC), in combination with pertuzumab as a first-line treatment for patients ...

Multivariable analyses confirmed that vaccination remained associated with lower hospitalization risk in both periods after controlling for comorbid conditions. Compared with vaccinated patients, the ...

Chronic kidney disease (CKD) is a well-established risk factor for cardiovascular (CV) disease because declining kidney ...

Chronic kidney disease (CKD) significantly amplifies cardiovascular (CV) risk, with CV disease remaining the leading cause of ...

The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

The report is based on the experience of a patient with recurrent retroperitoneal DDLPS and is believed to be the first reported case in which such a patient achieved a pathological complete response ...

AHA 2025 highlights included new guidelines and targeted approaches advancing heart failure and cardiovascular care. Our top coverage from this year’s American Heart Association (AHA) 2025 Scientific ...

Tom Kim, MD, of Sound Long-Term Care Management, discusses how serious illness and care coordination set these ACO patients ...

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...

Menin inhibitors target the interaction between menin and the KMT2A complex, offering a breakthrough in treating acute ...